Comparative Pharmacology
Head-to-head clinical analysis: CONSENSI versus MINODYL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CONSENSI versus MINODYL.
CONSENSI vs MINODYL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Consensi is a fixed-dose combination of amlodipine, a dihydropyridine calcium channel blocker, and celecoxib, a nonsteroidal anti-inflammatory drug (NSAID) that selectively inhibits cyclooxygenase-2 (COX-2). Amlodipine inhibits calcium ion influx across cardiac and vascular smooth muscle cells, leading to vasodilation and reduced blood pressure. Celecoxib inhibits prostaglandin synthesis via COX-2, reducing inflammation and pain.
Minodronic acid inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone and inhibiting farnesyl pyrophosphate synthase (FPPS) in the mevalonate pathway, thereby preventing protein prenylation and inducing osteoclast apoptosis.
Adults: 0.25 mg/kg intravenously over 1 hour every 2 weeks.
5-10 mg orally twice daily, with or without food.
None Documented
None Documented
Terminal elimination half-life of 12-15 hours for parent drug and 18-24 hours for active metabolite, allowing once-daily dosing.
Terminal elimination half-life: 4-5 hours; clinical context: requires twice-daily dosing for sustained antihypertensive effect.
Primarily renal (70-80% as unchanged drug and active metabolite desmethyl-consensi); biliary/fecal: 15-20%.
Renal: 90-95% (primarily as metabolites, ~5% unchanged); Fecal: <5%
Category C
Category C
Antihypertensive/NSAID Combination
Antihypertensive